A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

Recruiting in Palo Alto (17 mi)

+54 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Mural Oncology, Inc

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

To better understand the safety and tolerability of ALKS 4230 in humans

Eligibility Criteria

Inclusion Criteria

If you are participating in Part B or Part C of the trial, you must have at least one visible lesion that can be considered as a target for treatment.

If you have taken experimental drugs, you need to wait at least 4 weeks before joining the study.

Subject can move around on their own, has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and has an estimated life expectancy of at least 3 months

See 8 more

Exclusion Criteria

Subject is currently pregnant or breastfeeding, or is planning to become pregnant during the study

Subjects with dyspnea at rest of requiring oxygen therapy

Subjects active autoimmune disease requiring systemic treatment within the past 30 days

See 15 more